France
Rarecells is a biotechnology startup based in France, founded in 2010. The company's slogan, "Detect and defeat cancer from its start through a simple blood draw," reflects its primary focus on early cancer diagnosis. Rarecells develops and commercializes the ISET technology to isolate Circulating Cancer Cells for medical research and early cancer detection.
Founded by Patrizia Paterlini Brechot, a Professor of Cell Biology and Oncology, Rarecells® Diagnostics aims to make scientific and technological advances available to research teams and patients. The company holds the exclusive license for the patented ISET® (Isolation by SizE of Tumor cells) Technology, developed in collaboration with well-respected French Public Institutions including University Paris Descartes, Assistance Publique Hôpitaux de Paris, and INSERM.
The recent milestone for Rarecells is the $5.00M Series A investment secured on 09 December 2021. The investors involved in this funding round are currently undisclosed. Rarecells emphasizes its commitment to delivering customer satisfaction by manufacturing high-quality products and providing scientific assistance to its customers.
Rarecells® and ISET® are registered trademarks of Rarecells SAS, illustrating the company's dedication to its scientific approach and its pursuit of benefits for patients and the scientific community.
